Credits Available: 4.50 AMA PRA Category 1 Credit™ & 4.50 MOC points

Description: Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology

Kai He

The Ohio State University
Associate Professor

I am a Medical Oncologist and Associate Professor of Medicine with Tenure in the Thoracic Oncology Program at The Ohio State University James Cancer Center, focusing on cancer genomics and immunology, and the associated novel biomarker and therapeutic development in lung cancer. I am also a member of the OSUCCC Translational Therapeutics Program, Cancer Cell Therapy program, and Pelotonia Institute for Immuno-Oncology. I am the committee member of the OSUCCC Clinical Scientific Review Committee and Cell Therapy Committee.